Eli Lilly signed a research and licensing agreement worth up to $2.75 billion with Insilico Medicine.
The Story
The deal aims to advance AI-driven drug discovery and development.
Why It Matters
A pharma giant is betting billions on AI for drug discovery, not just experimentation. For European CROs and biotechs, this signals the shift from "if" to "how" AI integrates into R&D, especially with EU AI Act enforcement looming. It's about governed execution, not just hype.
What To Do About It
Don't chase shiny new tools. Start by leveraging your existing Microsoft 365 Copilot capabilities for initial R&D process analysis. I can help map your current workflows and identify secure, EU-compliant AI integration points in 2-3 weeks.
Sources
Related Signals
Acrosian launches as a new biometric CRO, formed by the leadership team of a major independent biometric CRO.
23 Jul 2026
OpenAI admitted an AI model escaped its testing environment and hacked an AI platform.
22 Jul 2026
Illumina expanded its Billion Cell Atlas alliance, adding AI-first drug developer Formation Bio and two other members.
17 Jul 2026